Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 999 999.9999 KRW
Market Cap: 71.2T KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+38%
Revenue
Forecast
+19%
Operating Income
Forecast
+25%
Net Income
Forecast
+23%

Wall Street
Price Targets

Price Targets Summary
Samsung Biologics Co Ltd

Wall Street analysts forecast Samsung Biologics Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 376 556.5217 KRW with a low forecast of 1 161 500 KRW and a high forecast of 1 680 000 KRW.

Lowest Forecast
Wall Street Target
1 161 500 KRW
16% Upside
Average Forecast
Wall Street Target
1 376 556.5217 KRW
38% Upside
Highest Forecast
Wall Street Target
1 680 000 KRW
68% Upside
Lowest
Price Target
1 161 500 KRW
16% Upside
Average
Price Target
1 376 556.5217 KRW
38% Upside
Highest
Price Target
1 680 000 KRW
68% Upside
Samsung Biologics Co Ltd Competitors:
Price Targets
688315
Novogene Co Ltd
0% Downside
CTKB
Cytek Biosciences Inc
33% Upside
CGEN
Compugen Ltd
425% Upside
R
RVTY
Revvity Inc
44% Upside
688315
Novogene Co Ltd
0% Downside
CTKB
Cytek Biosciences Inc
33% Upside
CGEN
Compugen Ltd
425% Upside
R
RVTY
Revvity Inc
44% Upside
SHC
Sotera Health Co
3% Upside
WST
West Pharmaceutical Services Inc
26% Upside
STVN
Stevanato Group SpA
10% Upside
S
237690
ST Pharm Co Ltd
33% Upside

Revenue
Forecast

Revenue Estimate
Samsung Biologics Co Ltd

For the last 10 years the compound annual growth rate for Samsung Biologics Co Ltd's revenue is 46%. The projected CAGR for the next 3 years is 19%.

46%
Past Growth
19%
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Samsung Biologics Co Ltd

The compound annual growth rate of Samsung Biologics Co Ltd's operating income for the next 3 years is 25%.

N/A
Past Growth
25%
Estimated Growth
Estimates Accuracy
2%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Samsung Biologics Co Ltd

The compound annual growth rate of Samsung Biologics Co Ltd's net income for the next 3 years is 23%.

N/A
Past Growth
23%
Estimated Growth
Estimates Accuracy
7%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Samsung Biologics Co Ltd's stock price target?
Price Target
1 376 556.5217 KRW

According to Wall Street analysts, the average 1-year price target for Samsung Biologics Co Ltd is 1 376 556.5217 KRW with a low forecast of 1 161 500 KRW and a high forecast of 1 680 000 KRW.

What is Samsung Biologics Co Ltd's Revenue forecast?
Projected CAGR
19%

For the last 10 years the compound annual growth rate for Samsung Biologics Co Ltd's revenue is 46%. The projected CAGR for the next 3 years is 19%.

What is Samsung Biologics Co Ltd's Operating Income forecast?
Projected CAGR
25%

The compound annual growth rate of Samsung Biologics Co Ltd's operating income for the next 3 years is 25%.

What is Samsung Biologics Co Ltd's Net Income forecast?
Projected CAGR
23%

The compound annual growth rate of Samsung Biologics Co Ltd's net income for the next 3 years is 23%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 283,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.